

Delphine Bachelet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7442658/publications.pdf>

Version: 2024-02-01

15
papers

608
citations

840776

11
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

1214
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	181
2	Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clinical Microbiology and Infection, 2021, 27, 1041.e1-1041.e4.	6.0	88
3	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Seminars in Arthritis and Rheumatism, 2019, 48, 967-975.	3.4	46
4	Determinants of serum concentrations of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls among French women in the CECILE study. Environmental Research, 2011, 111, 861-870.	7.5	43
5	Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS ONE, 2016, 11, e0162752.	2.5	41
6	Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. Journal of Hepatology, 2020, 72, 463-471.	3.7	38
7	Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. Journal of Medical Virology, 2021, 93, 2149-2159.	5.0	35
8	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12, e0170395.	2.5	34
9	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
10	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	2.3	22
11	A Case Study Addressing the Reliability of Polychlorinated Biphenyl Levels Measured at the Time of Breast Cancer Diagnosis in Representing Early-Life Exposure. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 281-286.	2.5	19
12	Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS ONE, 2019, 14, e0218258.	2.5	12
13	Breast Cancer and Exposure to Organochlorines in the CECILE Study: Associations with Plasma Levels Measured at the Time of Diagnosis and Estimated during Adolescence. International Journal of Environmental Research and Public Health, 2019, 16, 271.	2.6	12
14	CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis. Nephrology Dialysis Transplantation, 2021, 36, 2256-2262.	0.7	5
15	A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK Cohort. Frontiers in Immunology, 2020, 11, 608.	4.8	1